Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments
- 11 April 1986
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 255 (14) , 1887-1891
- https://doi.org/10.1001/jama.255.14.1887
Abstract
Research from JAMA — Stability and Inactivation of HTLV-III/LAV Under Clinical and Laboratory EnvironmentsThis publication has 11 references indexed in Scilit:
- INACTIVATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS BY HEAT, GAMMA RAYS, AND ULTRAVIOLET LIGHTThe Lancet, 1985
- INACTIVATION OF LYMPHADENOPATHY ASSOCIATED VIRUS BY CHEMICAL DISINFECTANTSThe Lancet, 1984
- Adaptation of Lymphadenopathy Associated Virus (LAV) to Replication in EBV-Transformed B Lymphoblastoid Cell LinesScience, 1984
- Selective Tropism of Lymphadenopathy Associated Virus (LAV) for Helper-Inducer T LymphocytesScience, 1984
- SEROEPIDEMIOLOGICAL STUDIES OF HUMAN T-LYMPHOTROPIC RETROVIRUS TYPE III IN ACQUIRED IMMUNODEFICIENCY SYNDROMEThe Lancet, 1984
- Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDSScience, 1984
- Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDSScience, 1984
- Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDSScience, 1984
- Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic ConsiderationsAnnals of Internal Medicine, 1984
- T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor.Proceedings of the National Academy of Sciences, 1980